BRK (BReast tumor Kinase),又称 PTK6 (Protein Tyrosine Kinase 6),是一种非受体酪氨酸激酶,包含 SH3、SH2 和 SH1 (酪氨酸激酶) 三大功能结构域。与 Src 家族的酪氨酸激酶不同,BRK 缺乏 N 端脂酰化位点,使其易于溶解并与细胞内底物相互作用。在正常组织中,BRK 表达水平较低,但在乳腺、卵巢和宫颈癌等多种肿瘤组织中高表达,且与肿瘤恶性程度及预后不良相关。
BRK 在癌症中主要通过促进增殖、抑制凋亡、增强侵袭与耐药性来发挥致癌作用。BRK 可作用于 EGFR、HER2、IGF-1R、STAT3 和 Akt 等多条信号通路,同时抑制 p27、Rb 等生长抑制因子,促进细胞周期进程。此外,BRK 还能通过调控 Paxillin、FAK 和 RhoA 促进细胞迁移和侵袭,并在低氧环境下被 HIF-1α 诱导表达,从而加速肿瘤转移。BRK 还影响化疗耐药性,如其高表达降低抗 HER2 化合物和抗 EGFR 化合物的敏感性。因此,BRK 被认为是具有价值的潜在肿瘤研究靶点[1]。
BRK (BReast tumor Kinase), also known as PTK6 (Protein Tyrosine Kinase 6), is a non-receptor tyrosine kinase that consists of three functional domains: SH3, SH2, and SH1 (tyrosine kinase). Unlike Src family tyrosine kinases, BRK lacks an N-terminal myristoylation site, making it more soluble and facilitating its interaction with intracellular substrates. In normal tissues, BRK expression is low, but it is highly upregulated in various tumors, including breast, ovarian, and cervical cancers, where its expression is associated with tumor malignancy and poor prognosis.
BRK exerts its oncogenic effects primarily by promoting proliferation, inhibiting apoptosis, enhancing invasion, and contributing to drug resistance. It activates multiple signaling pathways, including EGFR, HER2, IGF-1R, STAT3, and Akt, while suppressing tumor suppressors such as p27 and Rb, thereby facilitating cell cycle progression. Additionally, BRK regulates Paxillin, FAK, and RhoA, promoting cell migration and invasion, and is induced under hypoxic conditions by HIF-1α, further accelerating tumor metastasis. BRK also influences chemotherapy resistance, as its high expression reduces sensitivity to anti-HER2 and anti-EGFR compounds. Therefore, BRK is considered a valuable potential target for cancer research[1].
ALK/EGFR-IN-1-d5 (Compound (-)-9a) 是一种 EGFR 和 ALK 的氘代双靶点抑制剂,对 EGFR 的 IC50 值为 1.08 nM,对 ALK 的 IC50 值为 2.395 nM,通过抑制 EGFR、ALK 和 BRK 信号通路中的磷酸化蛋白来阻断细胞周期,从而导致肿瘤细胞的线粒体膜电位降低和细胞凋亡 (Apoptosis),也可在动物模型中显著抑制肿瘤生长并展现出良好的安全性,有望用于抗癌领域的研究。
BRK inhibitor P21d hydrochloride 是一种有效的乳腺肿瘤激酶(BRK/PTK6)抑制剂,IC50 为 30 nM,可以 52 nM 的 IC50 抑制 p-SAM68,并可用于评估 BRK 抑制剂在异种移植乳腺肿瘤模型中的体内活性。
BRK/PTK6-IN-1(Compound 51)是一种高效选择性 BRK 抑制剂(IC50 = 3.37 nM,Kd = 44 nM),在 MDA-MB-231 细胞中可降低 MMP-9 蛋白表达并抑制 IGF-1 诱导的 AKT 磷酸化,显著抑制迁移、侵袭和克隆形成而不影响细胞增殖,常用于乳腺癌等癌症的研究。
SB-633825 是一种有效的 ATP 竞争性 TIE2、LOK (STK10) 和 BRK 抑制剂,IC50 分别为 3.5 nM、66 nM 和 150 nM,可抑制癌细胞生长和血管生成。
Tilfrinib(化合物 4f)是一种高效、选择性的 Brk/PTK6 抑制剂,对 Brk 的 IC50 值为 3.15 nM,具有较好的抗增殖活性和抗肿瘤潜力。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号